Korro Bio Inc
KRRO15.000USD
+1.150+8.30%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
140.83MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Korro Bio Inc Unternehmen
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Unternehmensinformationen
BörsenkürzelKRRO
Name des UnternehmensKorro Bio Inc
IPO-datumOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Anzahl der mitarbeiter104
WertpapierartOrdinary Share
GeschäftsjahresendeOct 03
AddresseOne Kendall Square. Building 600-700
StadtCAMBRIDGE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02139
Telefon16174681999
Websitehttps://www.korrobio.com/
BörsenkürzelKRRO
IPO-datumOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Mr. Vineet Agarwal
Mr. Vineet Agarwal
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Katharine (Kate) Knobil, M.D.
Dr. Katharine (Kate) Knobil, M.D.
Independent Director
Independent Director
--
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Umsatzaufteilung
FY2025Q1
FY2024
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.55M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Deep Track Capital LP
9.31%
AllianceBernstein L.P.
7.25%
Fidelity Management & Research Company LLC
6.85%
Other
52.86%
Aktionäre
Aktionäre
Anteil
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Deep Track Capital LP
9.31%
AllianceBernstein L.P.
7.25%
Fidelity Management & Research Company LLC
6.85%
Other
52.86%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
29.04%
Hedge Fund
27.68%
Venture Capital
23.84%
Investment Advisor/Hedge Fund
21.97%
Corporation
5.75%
Research Firm
0.99%
Individual Investor
0.42%
Private Equity
0.34%
Bank and Trust
0.09%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
185
10.37M
110.42%
-208.38K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
2023Q2
235
150.53K
21.10%
-156.09K
2023Q1
266
144.14K
20.36%
-179.94K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Atlas Venture
1.14M
12.11%
--
--
Apr 15, 2025
New Enterprise Associates (NEA)
1.09M
11.62%
--
--
Mar 31, 2025
Deep Track Capital LP
874.61K
9.31%
--
--
Mar 31, 2025
AllianceBernstein L.P.
680.52K
7.25%
-25.28K
-3.58%
Mar 31, 2025
Fidelity Management & Research Company LLC
643.27K
6.85%
+1.53K
+0.24%
Mar 31, 2025
Driehaus Capital Management, LLC
582.45K
6.2%
+87.54K
+17.69%
Mar 31, 2025
Platanus Investment LLC
540.16K
5.75%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
520.89K
5.55%
+26.89K
+5.44%
Mar 31, 2025
Invus Public Equities Advisors, LLC
418.83K
4.46%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
407.81K
4.34%
-7.23K
-1.74%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Health Innovation Active ETF
0%
iShares Russell 3000 ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.02%
Avantis US Small Cap Equity ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0%
SPDR Portfolio MSCI Global Stock Market ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
iShares Health Innovation Active ETF
Anteil0%
iShares Russell 3000 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
Datum
Art
Verhältnis
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
